Search
Research
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA Randomized Trial): An unexpected observationThese findings may help to explain the decrease in external GW diagnoses seen in England.
Research
Utility of auscultatory screening for detecting rheumatic heart disease in high-risk children in Australia's Northern TerritorySensitivity and positive predictive value of cardiac auscultation compared with echocardiography is poor, regardless of the expertise of the auscultator.
Research
Genetic and epigenetic susceptibility to early life infectionTo date there have been relatively few studies on genetic determinants of susceptibility to neonatal infection and many of these have methodological...
Research
A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adultsNo currently licensed and available vaccine has been shown to provide broad protection against endemic MnB disease.
News & Events
The Kids Research Institute Australia leads WA arm of Australia’s first needle-free COVID-19 vaccine studyEnrolments for Australia’s first needle-free, gene-based COVID-19 vaccine study – to be led in WA by The Kids Research Institute Australia – are open.
Research
GAMA projectThis study investigated host gene expression in response to new HIV infection.
Research
MeaslesMeasles is a highly contagious infectious disease that can cause severe, long-term complications in children.
Research
Heritable and environmental determinants of hospitalisation for common childhood illnessesWe will leverage the unique Western Australian data linkage resources to undertake the definitive twin and sibling study of infection-related hospitalisation
Research
Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling studyThe Australian Therapeutic Goods Administration approved the use of nirsevimab, a long-acting monoclonal antibody for the prevention of Respiratory Syncytial Virus (RSV), in November 2023. Western Australia (WA) implemented a combination of nirsevimab administration strategies designed to protect all infants starting in April 2024, before the epidemic season. We developed a dynamic transmission model to predict the impact of WA's RSV immunisation program on infant hospitalisations.
Research
Impact of an evidence-based sepsis pathway on paediatric hospital clinical practice: A quality improvement studyTo assess the impact of implementing a sepsis pathway and education program on key sepsis outcomes and performance targets in a tertiary paediatric hospital.